RT Journal Article
SR Electronic
T1 771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients with advanced solid tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A866
OP A866
DO 10.1136/jitc-2023-SITC2023.0771
VO 11
IS Suppl 1
A1 Diab, Adi
A1 El-Khoueiry, Anthony
A1 Abdel-Wahab, Reham
A1 Thomas, Sajeve
A1 Hall, Evan
A1 Wu, Kaida
A1 Maciejewski, Benjamin S
A1 Mehta, Naveen K
A1 Liu, Laura
A1 Michaelson, Jennifer S
A1 Jones, Jeffrey A
A1 Sweis, Randy
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A866.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.